229 related articles for article (PubMed ID: 27430283)
1. mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review).
Hu K; Dai HB; Qiu ZL
Oncol Rep; 2016 Sep; 36(3):1219-25. PubMed ID: 27430283
[TBL] [Abstract][Full Text] [Related]
2. mTOR: An attractive therapeutic target for osteosarcoma?
Ding L; Congwei L; Bei Q; Tao Y; Ruiguo W; Heze Y; Bo D; Zhihong L
Oncotarget; 2016 Aug; 7(31):50805-50813. PubMed ID: 27177330
[TBL] [Abstract][Full Text] [Related]
3. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
Wang YT; Tang F; Hu X; Zheng CX; Gong TJ; Zhou Y; Luo Y; Min L
IUBMB Life; 2020 Oct; 72(10):2146-2153. PubMed ID: 33448097
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of X-Box Binding Protein 1 (XBP1) Correlates to Poor Prognosis and Up-Regulation of PI3K/mTOR in Human Osteosarcoma.
Yang J; Cheng D; Zhou S; Zhu B; Hu T; Yang Q
Int J Mol Sci; 2015 Dec; 16(12):28635-46. PubMed ID: 26633383
[TBL] [Abstract][Full Text] [Related]
5. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
6. [Inhibitory effect and significance of rapamycin on the mammalian target of rapamycin signaling pathway in osteosarcoma stem cells and osteosarcoma cells].
Liu PY; Zhang WB; Wang J; Shen YH; Wei YY
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):175-80. PubMed ID: 23879996
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways.
Qiu Q; Jiang J; Lin L; Cheng S; Xin D; Jiang W; Shen J; Hu Z
Int J Oncol; 2016 Jun; 48(6):2508-20. PubMed ID: 27082640
[TBL] [Abstract][Full Text] [Related]
8. Id-1 promotes osteosarcoma cell growth and inhibits cell apoptosis via PI3K/AKT signaling pathway.
Hao L; Liao Q; Tang Q; Deng H; Chen L
Biochem Biophys Res Commun; 2016 Feb; 470(3):643-649. PubMed ID: 26797271
[TBL] [Abstract][Full Text] [Related]
9. mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis.
Zhou Q; Deng Z; Zhu Y; Long H; Zhang S; Zhao J
Med Oncol; 2010 Dec; 27(4):1239-45. PubMed ID: 19936974
[TBL] [Abstract][Full Text] [Related]
10. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.
Perry JA; Kiezun A; Tonzi P; Van Allen EM; Carter SL; Baca SC; Cowley GS; Bhatt AS; Rheinbay E; Pedamallu CS; Helman E; Taylor-Weiner A; McKenna A; DeLuca DS; Lawrence MS; Ambrogio L; Sougnez C; Sivachenko A; Walensky LD; Wagle N; Mora J; de Torres C; Lavarino C; Dos Santos Aguiar S; Yunes JA; Brandalise SR; Mercado-Celis GE; Melendez-Zajgla J; Cárdenas-Cardós R; Velasco-Hidalgo L; Roberts CW; Garraway LA; Rodriguez-Galindo C; Gabriel SB; Lander ES; Golub TR; Orkin SH; Getz G; Janeway KA
Proc Natl Acad Sci U S A; 2014 Dec; 111(51):E5564-73. PubMed ID: 25512523
[TBL] [Abstract][Full Text] [Related]
11. PI3K/Akt signaling in osteosarcoma.
Zhang J; Yu XH; Yan YG; Wang C; Wang WJ
Clin Chim Acta; 2015 Apr; 444():182-92. PubMed ID: 25704303
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mTOR signaling by oleanolic acid contributes to its anti-tumor activity in osteosarcoma cells.
Zhou R; Zhang Z; Zhao L; Jia C; Xu S; Mai Q; Lu M; Huang M; Wang L; Wang X; Jin D; Bai X
J Orthop Res; 2011 Jun; 29(6):846-52. PubMed ID: 21246613
[TBL] [Abstract][Full Text] [Related]
13. LHX2 promotes malignancy and inhibits autophagy via mTOR in osteosarcoma and is negatively regulated by miR-129-5p.
Song H; Liu J; Wu X; Zhou Y; Chen X; Chen J; Deng K; Mao C; Huang S; Liu Z
Aging (Albany NY); 2019 Nov; 11(21):9794-9810. PubMed ID: 31724536
[TBL] [Abstract][Full Text] [Related]
14. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
15. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro.
Long XH; Zhang GM; Peng AF; Luo QF; Zhang L; Wen HC; Zhou RP; Gao S; Zhou Y; Liu ZL
Oncol Rep; 2014 Jan; 31(1):328-34. PubMed ID: 24172910
[TBL] [Abstract][Full Text] [Related]
17. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
[TBL] [Abstract][Full Text] [Related]
18. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
[TBL] [Abstract][Full Text] [Related]
19. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.
Fleuren ED; Versleijen-Jonkers YM; Roeffen MH; Franssen GM; Flucke UE; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
Int J Cancer; 2014 Dec; 135(12):2770-82. PubMed ID: 24771207
[TBL] [Abstract][Full Text] [Related]
20. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
